hC Bioscience, Inc

Is an innovator and pioneer of protein editing using gene and context agnostic engineered tRNA

Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.

About hC Bioscience

hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.

Science & Technology

Transfer RNA (tRNA) is the essential, often overlooked, molecule that provides the critical translation of genetic code into the proteins that are the building blocks of life. We are creating engineered tRNAs with the power to overcome disease-causing issues in the genetic code as proteins are made.

Focus

Team culture

We are building a diverse inclusive team of dedicated professionals.  Together our success will be born out of belief in our purpose, genuine love of what we are doing, and the integrity and excellence of our daily contributions.

“If you are working on something exciting that you really care about, you don’t have to be pushed. The vision pulls you.”

Our Leadership Team

Leslie J. Williams

Co-Founder, President & CEO​

Leslie J Williams, a 25-year biopharmaceutical industry veteran, is an experienced biotech CEO and board of directors’ member with demonstrated expertise in building companies, raising funds, and negotiating strategic collaborations.

David H. Altreuter​

CTO

Dave Altreuter, PhD is CTO at hC Bioscience.  Since 2001 Dave has specialized in the design, translation, and development of novel drug products wherein innovative delivery has a central or critically-enabling role.

Yosef Landesman

CSO

Dr. Landesman brings 20 years of experience in drug discovery, development, and regulatory approval in the biotech and pharmaceutical industries.

Gautam Goel

Chief Data Science Officer

Gautam is a leader in translational computational biology and a seasoned professional with an impactful 20-year track record in biotech, academia and tech industry.

Our Board of Directors

Steven Gillis

Chairman of Board | ARCH

Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a Founder and Director of Corixa Corporation and served as the company’s Chief Executive Officer.

David Moskowitz

8VC

David focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics.

Sacha Mann

Takeda Ventures

Sacha Mann is a Senior Partner at Takeda Ventures. She has a decade of experience in venture investing and complimentary skills in company creation, management as biotech CEO, business development, and R&D.

Brad Margus

Independent Board Director

Brad Margus currently serves as Executive Chair of Cerevance, a clinical-stage drug development company that he co-founded and led as Chief Executive Officer from 2016 to April 2022, focused on pursuing novel targets for brain diseases.

Benjamin Chen

Panacea Venture

Benjamin has been a partner at Panacea Venture since 2018, he is a scientist, entrepreneur, investor and merchant banker. 

Seiji Miyahara​

Taiho Ventures

Dr. Miyahara is a Senior Investment Director at Taiho Ventures with over 18 years of experience in the life sciences industry.

Leslie Williams

Co-Founder, President & CEO

Leslie J Williams, a 25-year biopharmaceutical industry veteran, is an experienced biotech CEO and board of directors’ member with demonstrated expertise in building companies, raising funds, and negotiating strategic collaborations.

Scientific Advisory Board

Craig Mello

PhD

Craig is Chairman of the Science Advisory Board and the Blais University Chair in Molecular Medicine at the University of Massachusetts Medical School (UMMS).

John DiPersio

MD, PhD

Dr. John F. DiPersio is Chief of the Division of Oncology, Deputy Director of the Siteman Cancer Center at Washington University School of Medicine in St. Louis, and the Virginia E. and Samuel J. Golman Professor of Medicine.

Page Bouchard

DVM

 Biotechnology Consultant

Page Bouchard is an independent biotechnology consultant with a focus on preclinical R&D and regulatory drug development.

Oladapo Yeku

MD, PhD

Dr. Oladapo Yeku is an Assistant Professor of Medicine at Harvard Medical School and a Clinical Assistant in Medicine at the Massachusetts General Hospital.

John Bell

PhD

Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England.

 Jeffrey M. Bockman

PhD

EVP, Head of Oncology Practice

Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting, formerly Defined Health. 

John Lueck

PhD

John Lueck is Assistant Professor in Department of Pharmacology and Physiology and is a member of The Center for RNA Biology the University of Rochester Medical Center

Christopher Ahern

PhD

Christopher Ahern is a Professor in the Department of Molecular Physiology and Biophysics and the Iowa Neuroscience Institute.

Martin Maier

PhD

Dr. Maier joined Alnylam Pharmaceuticals in 2006 where he currently serves as Senior Vice President, heading the Oncology group.

Career Opportunities

Full Time
Interested? Reach Out!

Partners & Collaborations

If you are interested in partnering with us, reach out here at info@hcbioscience.com

News

NOV 4, 2022

hC Bioscience Announces Extension of Series A to $40 Million

 

hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced an extension of $16 million to its Series A funding round, bringing the total raised to $40 million. Taiho Ventures and Panacea Venture joined existing investors, ARCH Venture Partners, Takeda Ventures and 8VC.

3d render biological cell virus

NOV 4, 2022

Mt. Everest almost got in the way of a tRNA biotech, but hC Bioscience climbs to Series A extension

A Takeda and ARCH-backed startup looking to prove out the next potential RNA goldmine in drug R&D has secured more capital en route to a 2024 clinical entry, CEO Leslie Williams tells Endpoints News.

 

 

 

SEP 13, 2022

hC Bioscience Appoints Brad Margus to its Board of Directors

hC Bioscience, Inc., a company developing first-
in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors.

“We are excited to welcome Brad to the company during this pivotal time of growth,”
said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience.

FEB 24, 2022

tRNA therapeutics burst onto startup scene

Nature Biotechnology (2022)

Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers…and the field continues to expand with the arrival of hC Bioscience, a startup that emerged from stealth mode in late February with $24 million and a plan to fight cancer and rare diseases with tRNA…

 

Featured

Sep 19, 2021

tRNA therapies could help restore proteins lost in translation

A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more

Publications

FEB 10, 2021

Therapeutic promise of engineered nonsense suppressor tRNAs

Nonsense mutations change an amino acid codon to a premature termination codon (PTC) generally through a single-nucleotide substitution…

FEB 18, 2019

Engineered transfer RNAs for suppression of premature termination codons

The appearance of the premature translation termination codons (PTCs)…